AU2009230799B2 — Melanocortin receptor ligands
Assigned to Ipsen Pharma SAS · Expires 2012-02-09 · 14y expired
What this patent protects
Abstract The present invention is directed to peptides which are ligands of one or more of the melanocortin receptors (MC-R), the pharmaceutically-acceptable salts thereof, to methods of using such peptides to treat mammals and to useful pharmaceutical compositions comprising sai…
USPTO Abstract
Abstract The present invention is directed to peptides which are ligands of one or more of the melanocortin receptors (MC-R), the pharmaceutically-acceptable salts thereof, to methods of using such peptides to treat mammals and to useful pharmaceutical compositions comprising said peptides. - 117 2098206_1 (GHatterm) WO 2007/008704 PCTIUS2006/026586 (6) P148eA uWOJ; sJ4 9 Uj pownsuot poo~j ul oouajojl ueew
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.